文献速递血液净化与透析水电解质与酸碱

蔗糖氢氧化氧铁联合碳酸钙在血液透析患者中的疗效与安全性

Efficacy and Safety of Sucroferric Oxyhydroxide and Calcium Carbonate in Hemodialysis Patients.
PubMed 文献 · Kidney Int Rep · 2017-10-06

这项III期、开放标签、单臂、多中心12周研究评估了蔗糖氢氧化氧铁(PA21)联合碳酸钙治疗血液透析合并高磷血症患者的疗效与安全性。35例患者从司维拉姆联合碳酸钙转换为蔗糖氢氧化氧铁联合碳酸钙,结果显示血清磷浓度维持达标,药物不良反应发生率为31.4%,腹泻最常见,患者排便满意度改善。

要点

  • 蔗糖氢氧化氧铁联合碳酸钙低剂量可维持血磷达标
  • 药物不良反应发生率31.4%,腹泻最常见
  • 患者排便满意度改善,药片负担减轻

核心结论

  • 蔗糖氢氧化氧铁联合碳酸钙低剂量可有效维持血磷在目标范围,并改善胃肠道状况。
  • 蔗糖氢氧化氧铁在减少药片负担的同时维持降磷效果,与碳酸钙联用耐受性良好。

研究设计与样本

  • III期、开放标签、单臂、多中心12周研究。
  • 纳入35例年龄≥20岁、接受每周3次血液透析、血清磷3.5-6.0 mg/dl且正在服用碳酸钙和司维拉姆的终末期肾病患者。
  • 患者从司维拉姆联合碳酸钙转换为蔗糖氢氧化氧铁联合碳酸钙治疗。

主要发现

  • 平均(SD)血清磷浓度在第0周为5.01(0.63)mg/dl,治疗结束时为4.89(1.14)mg/dl。
  • 药物不良反应发生率为31.4%(11/35),腹泻最常见(31.4%)。
  • 更多接受蔗糖氢氧化氧铁治疗的患者对排便满意,包括便秘和腹泻患者。

关键数值与推荐

  • 蔗糖氢氧化氧铁每日3次口服,每次250 mg至1000 mg(日剂量750-3000 mg),每餐前即刻服用,共12周。
  • 碳酸钙每日3次,每餐后口服。

临床怎么用

  • 对于血液透析高磷血症患者,可考虑蔗糖氢氧化氧铁联合碳酸钙方案以维持血磷达标并减少药片负担。
  • 需关注腹泻等胃肠道不良反应,但患者排便满意度可能改善。

局限性

  • 单臂设计,无对照,样本量较小(35例)。
  • 开放标签,可能存在偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: In this phase III, open-label, single-arm, multi-center 12-week study, we evaluated the efficacy and safety of combination therapy with sucroferric oxyhydroxide (PA21) and calcium carbonate for hemodialysis patients with hyperphosphatemia. METHODS: We enrolled 35 subjects aged ≥ 20 years with end-stage kidney disease and serum phosphorus 3.5-6.0 mg/dl who were undergoing hemodialysis 3 times weekly and taking calcium carbonate and sevelamer hydrochloride. Patients switched from sevelamer hydrochloride and calcium carbonate to sucroferric oxyhydroxide and calcium carbonate. Sucroferric oxyhydroxide was orally administered 3 times daily within 750 mg/d (250 mg per dose) to 3000 mg/d (1000 mg per dose), immediately before every meal, for 12 weeks. Calcium carbonate was orally administered 3 times daily after every meal. Outcomes were serum phosphorus concentration, safety, and satisfaction with bowel movements. RESULTS: Mean (SD) serum phosphorus concentrations were 5.01 (0.63) mg/dl at week 0 and 4.89 (1.14) mg/dl at the end of treatment, after patients switched from sevelamer hydrochloride to sucroferric oxyhydroxide. The incidence of adverse drug reactions was 31.4% (11/35), with diarrhea being the most frequent (31.4%). More sucroferric oxyhydroxide-treated patients were satisfied with their bowel movements. More patients with constipation, as well as those who experienced diarrhea, were satisfied with their bowel movements at the end of the study. CONCLUSION: Combined administration of sucroferric oxyhydroxide and calcium carbonate at low doses was effective in maintaining serum phosphorus concentrations within the target range, and patients' gastrointestinal status improved. Sucroferric oxyhydroxide maintained its serum phosphorus-lowering effect with a decreased pill burden, and its concomitant administration with calcium carbonate was well tolerated.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Koiwa F, Yokoyama K, Fukagawa M, et al. Efficacy and Safety of Sucroferric Oxyhydroxide and Calcium Carbonate in Hemodialysis Patients. Kidney Int Rep. 2017. PMID: 29340330. doi:10.1016/j.ekir.2017.10.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。